Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Clinical trial NCT00715637 · UNKNOWN

Trial details

NCT number: NCT00715637
Sponsor: Antisoma Research
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Start date: 2007-06-01
Primary completion: 2010-06-01
Enrollment: 420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.